Critical insights into the beneficial and protective actions of the kallikrein-kinin system

Vascular Pharmacology

Volumn 64, Issue , 2015, Pages 1-10

  Regoli, Domenico ^a   Gobeil, Fernand ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Ace inhibitors; Cardiovascular protection; Hypertension; Kinins

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KININ DERIVATIVE; SARTAN DERIVATIVE;

ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; COUGHING; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HOMEOSTASIS; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; THROMBOSIS; VASODILATATION; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; KALLIKREIN-KININ SYSTEM; MUSCLE, SMOOTH, VASCULAR; RENIN-ANGIOTENSIN SYSTEM;

EID: 84922610778     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.12.003     Document Type: Review

References (126)

1. Mancia G., Fagard R., Narkiewicz K., Redán J., Zanchetti A., Böhm M., et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013, 31:1925-1938.
2. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2013, 23:3-16.
3. Ruschitzka F., Taddei S. Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?. Eur Heart J 2012, 33:1996-1998.
4. Virdis A., Ghiadoni L., Taddei S. Clinical management of drug-induced hypertension. 2013 practical recommendations of the Italian Society of Hypertension (SIIA). High Blood Press Cardiovasc Prev 2014, 21:77-79.
5. Wehling M. Morbus diureticus in the elderly: epidemic overuse of a widely applied group of drugs. J Am Med Dir Assoc 2013, 14:437-442.
6. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005, 3:15-29.
7. Regoli D., Plante G.E., Gobeil F. Impact of kinins in the treatment of cardiovascular diseases. Pharmacol Ther 2012, 135:94-111.
8. Taddei S. New evidence for endothelial protection. Medicographia 2012, 34:17-22.
9. Dickinson C.J., Yu R. Mechanisms involved in the progressive pressor response to very small amounts of angiotensin in conscious rabbits. Circ Res 1967, 21(Suppl. 2). [157+].
10. Luft F.C., Wilcox C.S., Unger T., Kuhn R., Demmert G., Rohmeiss P., et al. Angiotensin-induced hypertension in the rat. Sympathetic nerve activity and prostaglandins. Hypertension 1989, 14:396-403.
11. Wu W., Zhang Y., Ballew J.R., Fink G., Wang D.H. Development of hypertension induced by subpressor infusion of angiotensin II: role of sensory nerves. Hypertension 2000, 36:549-552.
12. Navar L.G., Prieto M.C., Satou R., Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol 2011, 11:180-186.
13. Gross F., Schaechtelin G., Brunner H., Peters G. The role of the renin-angiotensin system In blood pressure regulation and kidney function. Can Med Assoc J 1964, 90:258-262.
14. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86:747-803.
15. Schmaier A.H. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int Immunopharmacol 2008, 8:161-165.
16. Vane J. Control of the circulation by endothelial mediators. Inaugural G.B. West Memorial Lecture. Int Arch Allergy Immunol 1993, 101:333-345.
17. Bovenzi V., Savard M., Morin J., Cuerrier C.M., Grandbois M., Gobeil F. Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli. J Cell Physiol 2010, 222:168-176.
18. Duka A., Duka I., Gao G., Shenouda S., Gavras I., Gavras H. Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. Am J Physiol Endocrinol Metab 2006, 291:E268-E274.
19. Loiola R.A., Reis F.C., Kawamoto E.M., Scavone C., Abdalla D.S., Fernandes L., et al. Role of vascular Kinin B1 and B2 receptors in endothelial nitric oxide metabolism. Peptides 2011, 32:1700-1705.
20. Gericke A., Sniatecki J.J., Mayer V.G., Goloborodko E., Patzak A., Wess J., et al. Role of M1, M3, and M5 muscarinic acetylcholine receptors in cholinergic dilation of small arteries studied with gene-targeted mice. Am J Physiol Heart Circ Physiol 2011, 300:H1602-H1608.
21. Hill S.J., Ganellin C.R., Timmerman H., Schwartz J.C., Shankley N.P., Young J.M., et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997, 49:253-278.
22. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006, 58:58-86.
23. Schmaier A.H. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 2002, 109:1007-1009.
24. Yayama K., Kunimatsu N., Teranishi Y., Takano M., Okamoto H. Tissue kallikrein is synthesized and secreted by human vascular endothelial cells. Biochim Biophys Acta 2003, 1593:231-238.
25. Schmaier A.H. Physiologic activities of the contact activation system. Thromb Res 2014, 133(Suppl. 1):S41-S44.
26. Mousli M., Bueb J.L., Bronner C., Rouot B., Landry Y. G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci 1990, 11:358-362.
27. Cruden N.L., Newby D.E. Clots, kinins and coronaries. Atherosclerosis 2005, 183:189-198.
28. Tiefenbacher C.P., Friedrich S., Bleeke T. ACE inhibitors improve endothelial function of coronary arterioles from patients with atherosclerosis by influencing local kinin release. J Am Coll Cardiol 2002, 39:223.
29. Cruden N.L., Lang N.N., MacGillivray T.J., Uren N.G., Fox K.A., Newby D.E. Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb. Heart Vessels 2012, 27:179-185.
30. Murphey L., Vaughan D., Brown N. Contribution of bradykinin to the cardioprotective effects of ACE inhibitors. Eur Heart J Suppl 2003, 5:A37-A41.
31. Hornig B., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997, 95:1115-1118.
32. Enseleit F., Hurlimann D., Luscher T.F. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol 2001, 37(Suppl. 1):S21-S30.
33. Cravedi P., Ruggenenti P., Remuzzi G. Which antihypertensive drugs are the most nephroprotective and why?. Expert Opin Pharmacother 2010, 11:2651-2663.
34. Unger T. Decade in review-hypertension: the past decade in hypertension-facts, hopes, and hypes. Nat Rev Cardiol 2014, 11:633-635.
35. McFarlane S.I., Kumar A., Sowers J.R. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H-37H.
36. Dorer F.E., Kahn J.R., Lentz K.E., Levine M., Skeggs L.T. Hydrolysis of bradykinin by angiotensin-converting enzyme. Circ Res 1974, 34:824-827.
37. Jaspard E., Wei L., Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993, 268:9496-9503.
38. Ceconi C., Francolini G., Olivares A., Comini L., Bachetti T., Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007, 577:1-6.
39. Kakoki M., Sullivan K.A., Backus C., Hayes J.M., Oh S.S., Hua K., et al. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci U S A 2010, 107:10190-10195.
40. Kayashima Y., Smithies O., Kakoki M. The kallikrein-kinin system and oxidative stress. Curr Opin Nephrol Hypertens 2012, 21:92-96.
41. Tomita H., Sanford R.B., Smithies O., Kakoki M. The kallikrein-kinin system in diabetic nephropathy. Kidney Int 2012, 81:733-744.
42. Alhenc-Gelas F., Bouby N., Richer C., Potier L., Roussel R., Marre M. Kinins as therapeutic agents in cardiovascular and renal diseases. Curr Pharm Des 2011, 17:2654-2662.
43. Duncan A.M., Kladis A., Jennings G.L., Dart A.M., Esler M., Campbell D.J. Kinins in humans. Am J Physiol Regul Integr Comp Physiol 2000, 278:R897-R904.
44. Linz W., Wiemer G., Gohlke P., Unger T., Scholkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995, 47:25-49.
45. Pellacani A., Brunner H.R., Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond) 1994, 87:567-574.
46. Ferrari R. Treatment with angiotensin-converting enzyme inhibitors: insight into perindopril cardiovascular protection. Eur Heart J Suppl 2008, 10:G13-G20.
47. Couture R., Blaes N., Girolami J.P. Kinin receptors in vascular biology and pathology. Curr Vasc Pharmacol 2014, 12:223-248.
48. Kakoki M., Smithies O. The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int 2009, 75:1019-1030.
49. Krankel N., Katare R.G., Siragusa M., Barcelos L.S., Campagnolo P., Mangialardi G., et al. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res 2008, 103:1335-1343.
50. Hoshida S., Yamashita N., Kawahara K., Kuzuya T., Hori M. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: possible mechanisms. Circulation 1999, 99:434-440.
51. Blaes N., Girolami J.P. Targeting the 'Janus face' of the B2-bradykinin receptor. Expert Opin Ther Targets 2013, 17:1145-1166.
52. Chao J., Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol 2005, 90:291-298.
53. Campbell D.J., Kladis A., Duncan A.M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994, 23:439-449.
54. Murphey L.J., Malave H.A., Petro J., Biaggioni I., Byrne D.W., Vaughan D.E., et al. Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. J Pharmacol Exp Ther 2006, 318:1287-1292.
55. Savard M., Labonte J., Dubuc C., Neugebauer W., D'Orleans-Juste P., Gobeil F. Further pharmacological evaluation of a novel synthetic peptide bradykinin B2 receptor agonist. Biol Chem 2013, 394:353-360.
56. Balaguer J.M., Yu C., Byrne J.G., Ball S.K., Petracek M.R., Brown N.J., et al. Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial. Clin Pharmacol Ther 2013, 93:326-334.
57. Lucking A.J., Gibson K.R., Paterson E.E., Faratian D., Ludlam C.A., Boon N.A., et al. Endogenous tissue plasminogen activator enhances fibrinolysis and limits thrombus formation in a clinical model of thrombosis. Arterioscler Thromb Vasc Biol 2013, 33:1105-1111.
58. Smith D., Gilbert M., Owen W.G. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985, 66:835-839.
59. Girnys E.A., Porter V.R., Mosberg H.I. Conformationally restricted analogs of the direct thrombin inhibitor FM 19. Bioorg Med Chem 2011, 19:7425-7434.
60. Nieman M.T., Burke F., Warnock M., Zhou Y., Sweigart J., Chen A., et al. Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo. J Thromb Haemost 2008, 6:837-845.
61. Prieto A.R., Ma H., Huang R., Khan G., Schwartz K.A., Hage-Korban E.E., et al. Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury. Cardiovasc Res 2002, 53:984-992.
62. Battegay E.J., de Miguel L.S., Petrimpol M., Humar R. Effects of anti-hypertensive drugs on vessel rarefaction. Curr Opin Pharmacol 2007, 7:151-157.
63. Kakoki M., Kizer C.M., Yi X., Takahashi N., Kim H.S., Bagnell C.R., et al. Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest 2006, 116:1302-1309.
64. Pretorius M., Rosenbaum D., Vaughan D.E., Brown N.J. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 2003, 107:579-585.
65. Ceconi C., Francolini G., Bastianon D., Gitti G.L., Comini L., Ferrari R. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007, 21:423-429.
66. Ferrari R., Guardigli G., Ceconi C. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. Cardiovasc Drugs Ther 2010, 24:331-339.
67. Oeseburg H., Iusuf D., van der Harst P., van Gilst W.H., Henning R.H., Roks A.J. Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension 2009, 53:417-422.
68. Remme W.J. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?. Drugs 1997, 54(Suppl. 5):59-70.
69. Krankel N., Kuschnerus K., Muller M., Speer T., Mocharla P., Madeddu P., et al. Novel insights into the critical role of bradykinin and the kinin B2 receptor for vascular recruitment of circulating endothelial repair-promoting mononuclear cell subsets: alterations in patients with coronary disease. Circulation 2013, 127:594-603.
70. Krankel N., Madeddu P. Helping the circulatory system heal itself: manipulating kinin signaling to promote neovascularization. Expert Rev Cardiovasc Ther 2009, 7:215-219.
71. Ghiadoni L., Magagna A., Versari D., Kardasz I., Huang Y., Taddei S., et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003, 41:1281-1286.
72. Ceconi C., Fox K.M., Remme W.J., Simoons M.L., Bertrand M., Parrinello G., et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007, 73:237-246.
73. Ghiadoni L., Versari D., Magagna A., Kardasz I., Plantinga Y., Giannarelli C., et al. Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hypertens 2007, 25:361-366.
74. van Sloten T.T., Henry R.M., Dekker J.M., Nijpels G., Unger T., Schram M.T., et al. Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the hoorn study. Hypertension 2014, 64:1299-1305.
75. Dias J.P., Couture R. Blockade of kinin B(1) receptor reverses plasma fatty acids composition changes and body and tissue fat gain in a rat model of insulin resistance. Diabetes Obes Metab 2012, 14:244-253.
76. El Midaoui A., de Champlain J. Effects of glucose and insulin on the development of oxidative stress and hypertension in animal models of type 1 and type 2 diabetes. J Hypertens 2005, 23:581-588.
77. Dias J.P., Talbot S., Senecal J., Carayon P., Couture R. Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications. PLoS One 2010, 5:e12622.
78. Bhat M., Pouliot M., Couture R., Vaucher E. The kallikrein-kinin system in diabetic retinopathy. Prog Drug Res 2014, 69:111-143.
79. Clermont A., Chilcote T.J., Kita T., Liu J., Riva P., Sinha S., et al. Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes 2011, 60:1590-1598.
80. Feener E.P., Zhou Q., Fickweiler W. Role of plasma kallikrein in diabetes and metabolism. Thromb Haemost 2013, 110:434-441.
81. Pruneau D., Belichard P., Sahel J.A., Combal J.P. Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy. Curr Opin Investig Drugs 2010, 11:507-514.
82. Villa E., Rabano A., Ruilope L.M., Garcia-Robles R. Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997, 10:202-208.
83. Delemasure S., Blaes N., Richard C., Couture R., Bader M., Dutartre P., et al. Antioxidant/oxidant status and cardiac function in bradykinin B(1)- and B(2)-receptor null mice. Physiol Res 2013, 62:511-517.
84. Hock F.J., Wirth K., Albus U., Linz W., Gerhards H.J., Wiemer G., et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991, 102:769-773.
85. Wirth K., Hock F.J., Albus U., Linz W., Alpermann H.G., Anagnostopoulos H., et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991, 102:774-777.
86. Bhardwaj N., Craig T.J. Treatment of hereditary angioedema: a review. Transfusion 2014, 54:2989-2996.
87. Cicardi M., Banerji A., Bracho F., Malbrán A., Rosenkranz B., Riedl M., et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010, 363:532-541.
88. Brown N.J., Vaughan D.E. Angiotensin-converting enzyme inhibitors. Circulation 1998, 97:1411-1420.
89. Gavras H. Corcoran lecture. Angiotensin-converting enzyme inhibition and the heart. Hypertension 1994, 23:813-818.
90. Yao Y., Sheng Z., Li Y., Yan F., Fu C., Li Y., et al. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther 2012, 23:859-870.
91. Carretero O.A., Scicli A.G. Kinin paracrine hormone. The kallikrein-kinin system in health and disease 1989, 63-78. Limbach-Verlag Braunschweig, Munich, Germany. H. Fritz, I. Schmidt, G. Dietze (Eds.).
92. Chao J., Bledsoe G., Chao L. Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res 2014, 69:37-57.
93. Chao J., Shen B., Gao L., Xia C.F., Bledsoe G., Chao L. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem 2010, 391:345-355.
94. Girolami J.P., Blaes N., Bouby N., Alhenc-Gelas F. Genetic manipulation and genetic variation of the kallikrein-kinin system: impact on cardiovascular and renal diseases. Prog Drug Res 2014, 69:145-196.
95. Kolodka T., Charles M.L., Raghavan A., Radichev I.A., Amatya C., Ellefson J., et al. Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus. PLoS One 2014, 9:e103981.
96. Potier L., Waeckel L., Vincent M.P., Chollet C., Gobeil F., Marre M., et al. Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes. J Pharmacol Exp Ther 2013, 346:23-30.
97. Su J.B. Kinins and cardiovascular diseases. Curr Pharm Des 2006, 12:3423-3435.
98. Uzawa A., Mori M., Taniguchi J., Kuwabara S. Modulation of kallikrein-kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis. Clin Exp Immunol 2014, 178:245.
99. Desposito D., Potier L., Chollet C., Gobeil F., Roussel R., Bouby N., et al. Kinin receptor agonism restores hindlimb postischemic neovascularization capacity in diabetic mice. J Pharmacol Exp Ther 2015, [in press].
100. Waeckel L., Potier L., Richer C., Roussel R., Bouby N., Alhenc-Gelas F. Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man. Thromb Haemost 2013, 110:476-483.
101. James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA 2014, 311:507.
102. Dasgupta K., Quinn R.R., Zarnke K.B., Rabi D.M., Ravani P., Daskalopoulou S.S., et al. The 2014 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014, 30:485-501.
103. Sindone A., Erlich J., Perkovic V., Suranyi M., Newman H., Lee C., et al. ACEIs for cardiovascular risk reduction-have we taken our eye off the ball?. Aust Fam Physician 2013, 42:634-638.
104. van Vark L.C., Bertrand M., Akkerhuis K.M., Brugts J.J., Fox K., Mourad J.J., et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012, 33:2088-2097.
105. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002, 288:2981.
106. Erdös E.G. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990, 15(Suppl. 6):S20-S24.
107. Ng K.K., Vane J.R. Some properties of angiotensin converting enzyme in the lung in vivo. Nature 1970, 225:1142-1144.
108. Zhu L., Carretero O.A., Liao T.D., Harding P., Li H., Sumners C., et al. Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 2010, 56:384-390.
109. Campbell D.J., Krum H., Esler M.D. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005, 111:315-320.
110. LeFebvre J., Shintani A., Gebretsadik T., Petro J.R., Murphey L.J., Brown N.J. Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade. J Pharmacol Exp Ther 2007, 320:1261-1267.
111. Squire I.B., O'Kane K.P., Anderson N., Reid J.L. Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension 2000, 36:132-136.
112. Carey R.M., Padia S.H. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 2008, 19:84-87.
113. Hofer-Dueckelmann C., Prinz E., Beindl W., Szymanski J., Fellhofer G., Pichler M., et al. Adverse drug reactions (ADRs) associated with hospital admissions-elderly female patients are at highest risk. Int J Clin Pharmacol Ther 2011, 49:577-586.
114. Bezalel S., Mahlab-Guri K., Asher I., Werner B., Sthoeger Z.M. Angiotensin converting enzyme inhibitor induced angioedema. Am J Med 2014, [Epub ahead of print]. 10.1016/j.amjmed.2014.1007.1011.
115. Brugts J.J., Arima H., Remme W., Bertrand M., Ferrari R., Fox K., et al. The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease. Int J Cardiol 2014, [Epub ahead of print]. 10.1016/j.ijcard.2014.07.108.
116. Makani H., Messerli F.H., Romero J., Wever-Pinzon O., Korniyenko A., Berrios R.S., et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 2012, 110:383-391.
117. Agabiti-Rosei E., Ambrosioni E., Finardi G., Folino P., Gambassi G., Malini P., et al. Perindopril versus captopril: efficacy and acceptability in an Italian multicenter trial. Am J Med 1992, 92:79S-83S.
118. David D., Jallad N., Germino F.W., Willett M.S., de Silva J., Weidner S.M., et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor-associated cough. Am J Ther 1995, 2:806-813.
119. Brown N.J., Ray W.A., Snowden M., Griffin M.R. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996, 60:8-13.
120. Tumanan-Mendoza B.A., Dans A.L., Villacin L.L., Mendoza V.L., Rellama-Black S., Bartolome M., et al. Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is. J Clin Epidemiol 2007, 60:547-553.
121. Paulis L., Steckelings U.M., Unger T. Key advances in antihypertensive treatment. Nat Rev Cardiol 2012, 9:276-285.
122. Imaizumi S., Miura S., Yahiro E., Uehara Y., Komuro I., Saku K. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des 2013, 19:3002-3008.
123. Dorrance A.M. Interfering with mineralocorticoid receptor activation: the past, present, and future. F1000Prime Rep 2014, 6:61.
124. Namsolleck P., Unger T. Aldosterone synthase inhibitors in cardiovascular and renal diseases. Nephrol Dial Transplant 2014, 29(Suppl. 1):i62-i68.
125. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014, 371:993-1004.
126. Violin J.D., Crombie A.L., Soergel D.G., Lark M.W. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci 2014, 35:308-316.